These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 32718811)

  • 21. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
    Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.
    Xu S; Huang H; Huang Y; Qian J; Wang X; Xu Z; Liu S; Liu J
    JAMA Surg; 2023 Jan; 158(1):73-79. PubMed ID: 36449303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients.
    Moten AS; Zhao H; Willis AI
    Surg Oncol; 2019 Jun; 29():184-189. PubMed ID: 31196486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Propensity score matching analysis of adjuvant external-beam radiotherapy for the treatment of papillary thyroid carcinoma with other organ invasions.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Jun; 80(3):589-599. PubMed ID: 36600104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
    Zevallos JP; Xu L; Yiu Y
    Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
    Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
    Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
    Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
    Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
    [No Abstract]   [Full Text] [Related]  

  • 31. Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study.
    He T; Li M; Gao ZL; Li XY; Zhong HR; Ding CS; Cai HW
    Nucl Med Commun; 2024 Sep; 45(9):779-787. PubMed ID: 38832411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
    Dai P; Zhao W; Zheng X; Luo H; Wang X
    J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
    Chandekar KR; Satapathy S; Bal C
    Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
    Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
    Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
    Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
    Grigsby PW; Reddy RM; Moley JF; Hall BL
    Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
    Watanabe K; Igarashi T; Uchiyama M; Ojiri H
    Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
    Rosario PW; Mourão GF; Calsolari MR
    Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.